Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome
Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2002-05, Vol.61 (5), p.414-421 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 421 |
---|---|
container_issue | 5 |
container_start_page | 414 |
container_title | Annals of the rheumatic diseases |
container_volume | 61 |
creator | Williams, F M K Chinn, S Hughes, G R V Leach, R M |
description | Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival. |
doi_str_mv | 10.1136/ard.61.5.414 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A86035266</galeid><sourcerecordid>A86035266</sourcerecordid><originalsourceid>FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</originalsourceid><addsrcrecordid>eNp9kt-L1DAQx4Mo3t7pm89SFPHFrknzo-nLwbl4_uA45fDHY0jTdDdrm6xJe7j_vbNsuT1hkRCGyXzynclkEHpG8JwQKt7q2MwFmfM5I-wBmhEmZF5ggR-iGcaY5qwS5Qk6TWkNLpZEPkYnhFS8KgWfoZtFdIMzustc13mbUuZ8lrZpsL0zWTduxpTZuB1WttdDSOBp32Tggh3cZhUS7M5tXAO3fBNDb5-gR63ukn062TP0_fL9t8XH_OrLh0-Li6u85gVnudAFrZmUuqZlU2lmGDUSC4MbVtSyopJUzNq6agsmGeGSsRZL04oGjKgNpmfofK-7GeveNsb6IepObaLrddyqoJ36N-LdSi3DrSIlZ7jiIPByEojh92jToNZhjB5qBqQsIWPJK6Be7Kml7qxyvg0gZnqXjLqQAlNeCAHQmyPQ0noLiYO3rYPj-3h-BIfV7Np-jJ_kTQwpRdvevZJgtZsCBVOgBFFcwRQA_vx-Zw7w9O0AvJoAneDv26i9cenAUUFZQeShTgcD8ecuruMvJUpacnX9Y6Gub8jnd5c_v6od_3rP1_36_yX-Bfmt1iY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777844759</pqid></control><display><type>article</type><title>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Williams, F M K ; Chinn, S ; Hughes, G R V ; Leach, R M</creator><creatorcontrib>Williams, F M K ; Chinn, S ; Hughes, G R V ; Leach, R M</creatorcontrib><description>Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.61.5.414</identifier><identifier>PMID: 11959765</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Acute Physiology and Chronic Health Evaluation (score) ; acute respiratory distress syndrome ; Adolescent ; Adult ; Age Factors ; Age of Onset ; Aged ; ANA ; Anticoagulants ; Antigens ; antinuclear antibodies ; Antiphospholipid syndrome ; Antiphospholipid Syndrome - drug therapy ; Antiphospholipid Syndrome - mortality ; APACHE ; APS ; ARDS ; Biological and medical sciences ; C reactive protein ; Child ; confidence interval ; Critical Care ; Critical Illness ; CRP ; Cyclophosphamide - therapeutic use ; Development and progression ; ENA ; erythrocyte sedimentation rate ; ESR ; Extended Report ; extractable nuclear antigens ; Female ; Hematology ; Humans ; ICU ; Illnesses ; Immunoglobulins ; Immunosuppressive Agents - therapeutic use ; Infections ; intensive care ; intensive care unit ; Intensive care units ; Kidney diseases ; Kidney Diseases - drug therapy ; Kidney Diseases - mortality ; Laboratories ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - mortality ; Male ; Medical prognosis ; Medical sciences ; Middle Aged ; Mortality ; Physiology ; Prednisolone - therapeutic use ; Proportional Hazards Models ; Regression Analysis ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; SLE ; Survival Rate ; Systemic lupus erythematosus ; Thrombosis ; WCC ; white cell count</subject><ispartof>Annals of the rheumatic diseases, 2002-05, Vol.61 (5), p.414-421</ispartof><rights>Copyright 2002 by Annals of the Rheumatic Diseases</rights><rights>2002 INIST-CNRS</rights><rights>COPYRIGHT 2002 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2002 Copyright 2002 by Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</citedby><cites>FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754095/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754095/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13634218$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11959765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Williams, F M K</creatorcontrib><creatorcontrib>Chinn, S</creatorcontrib><creatorcontrib>Hughes, G R V</creatorcontrib><creatorcontrib>Leach, R M</creatorcontrib><title>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.</description><subject>Acute Physiology and Chronic Health Evaluation (score)</subject><subject>acute respiratory distress syndrome</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>ANA</subject><subject>Anticoagulants</subject><subject>Antigens</subject><subject>antinuclear antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Antiphospholipid Syndrome - drug therapy</subject><subject>Antiphospholipid Syndrome - mortality</subject><subject>APACHE</subject><subject>APS</subject><subject>ARDS</subject><subject>Biological and medical sciences</subject><subject>C reactive protein</subject><subject>Child</subject><subject>confidence interval</subject><subject>Critical Care</subject><subject>Critical Illness</subject><subject>CRP</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Development and progression</subject><subject>ENA</subject><subject>erythrocyte sedimentation rate</subject><subject>ESR</subject><subject>Extended Report</subject><subject>extractable nuclear antigens</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>ICU</subject><subject>Illnesses</subject><subject>Immunoglobulins</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infections</subject><subject>intensive care</subject><subject>intensive care unit</subject><subject>Intensive care units</subject><subject>Kidney diseases</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - mortality</subject><subject>Laboratories</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Physiology</subject><subject>Prednisolone - therapeutic use</subject><subject>Proportional Hazards Models</subject><subject>Regression Analysis</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>SLE</subject><subject>Survival Rate</subject><subject>Systemic lupus erythematosus</subject><subject>Thrombosis</subject><subject>WCC</subject><subject>white cell count</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kt-L1DAQx4Mo3t7pm89SFPHFrknzo-nLwbl4_uA45fDHY0jTdDdrm6xJe7j_vbNsuT1hkRCGyXzynclkEHpG8JwQKt7q2MwFmfM5I-wBmhEmZF5ggR-iGcaY5qwS5Qk6TWkNLpZEPkYnhFS8KgWfoZtFdIMzustc13mbUuZ8lrZpsL0zWTduxpTZuB1WttdDSOBp32Tggh3cZhUS7M5tXAO3fBNDb5-gR63ukn062TP0_fL9t8XH_OrLh0-Li6u85gVnudAFrZmUuqZlU2lmGDUSC4MbVtSyopJUzNq6agsmGeGSsRZL04oGjKgNpmfofK-7GeveNsb6IepObaLrddyqoJ36N-LdSi3DrSIlZ7jiIPByEojh92jToNZhjB5qBqQsIWPJK6Be7Kml7qxyvg0gZnqXjLqQAlNeCAHQmyPQ0noLiYO3rYPj-3h-BIfV7Np-jJ_kTQwpRdvevZJgtZsCBVOgBFFcwRQA_vx-Zw7w9O0AvJoAneDv26i9cenAUUFZQeShTgcD8ecuruMvJUpacnX9Y6Gub8jnd5c_v6od_3rP1_36_yX-Bfmt1iY</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>Williams, F M K</creator><creator>Chinn, S</creator><creator>Hughes, G R V</creator><creator>Leach, R M</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>BMJ Publishing Group Ltd</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20020501</creationdate><title>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</title><author>Williams, F M K ; Chinn, S ; Hughes, G R V ; Leach, R M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Acute Physiology and Chronic Health Evaluation (score)</topic><topic>acute respiratory distress syndrome</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>ANA</topic><topic>Anticoagulants</topic><topic>Antigens</topic><topic>antinuclear antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Antiphospholipid Syndrome - drug therapy</topic><topic>Antiphospholipid Syndrome - mortality</topic><topic>APACHE</topic><topic>APS</topic><topic>ARDS</topic><topic>Biological and medical sciences</topic><topic>C reactive protein</topic><topic>Child</topic><topic>confidence interval</topic><topic>Critical Care</topic><topic>Critical Illness</topic><topic>CRP</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Development and progression</topic><topic>ENA</topic><topic>erythrocyte sedimentation rate</topic><topic>ESR</topic><topic>Extended Report</topic><topic>extractable nuclear antigens</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>ICU</topic><topic>Illnesses</topic><topic>Immunoglobulins</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infections</topic><topic>intensive care</topic><topic>intensive care unit</topic><topic>Intensive care units</topic><topic>Kidney diseases</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - mortality</topic><topic>Laboratories</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Physiology</topic><topic>Prednisolone - therapeutic use</topic><topic>Proportional Hazards Models</topic><topic>Regression Analysis</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>SLE</topic><topic>Survival Rate</topic><topic>Systemic lupus erythematosus</topic><topic>Thrombosis</topic><topic>WCC</topic><topic>white cell count</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Williams, F M K</creatorcontrib><creatorcontrib>Chinn, S</creatorcontrib><creatorcontrib>Hughes, G R V</creatorcontrib><creatorcontrib>Leach, R M</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Williams, F M K</au><au>Chinn, S</au><au>Hughes, G R V</au><au>Leach, R M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>61</volume><issue>5</issue><spage>414</spage><epage>421</epage><pages>414-421</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>11959765</pmid><doi>10.1136/ard.61.5.414</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2002-05, Vol.61 (5), p.414-421 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754095 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Acute Physiology and Chronic Health Evaluation (score) acute respiratory distress syndrome Adolescent Adult Age Factors Age of Onset Aged ANA Anticoagulants Antigens antinuclear antibodies Antiphospholipid syndrome Antiphospholipid Syndrome - drug therapy Antiphospholipid Syndrome - mortality APACHE APS ARDS Biological and medical sciences C reactive protein Child confidence interval Critical Care Critical Illness CRP Cyclophosphamide - therapeutic use Development and progression ENA erythrocyte sedimentation rate ESR Extended Report extractable nuclear antigens Female Hematology Humans ICU Illnesses Immunoglobulins Immunosuppressive Agents - therapeutic use Infections intensive care intensive care unit Intensive care units Kidney diseases Kidney Diseases - drug therapy Kidney Diseases - mortality Laboratories Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - mortality Male Medical prognosis Medical sciences Middle Aged Mortality Physiology Prednisolone - therapeutic use Proportional Hazards Models Regression Analysis Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis SLE Survival Rate Systemic lupus erythematosus Thrombosis WCC white cell count |
title | Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A37%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Critical%20illness%20in%20systemic%20lupus%20erythematosus%20and%20the%20antiphospholipid%20syndrome&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Williams,%20F%20M%20K&rft.date=2002-05-01&rft.volume=61&rft.issue=5&rft.spage=414&rft.epage=421&rft.pages=414-421&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.61.5.414&rft_dat=%3Cgale_pubme%3EA86035266%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777844759&rft_id=info:pmid/11959765&rft_galeid=A86035266&rfr_iscdi=true |